Robbins LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Ocular Therapeutix, Inc. (NasdaqGM: OCUL) breached their fiduciary duties to shareholders. Ocular, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology.

Ocular Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact us via the form below and we will contact you directly.